N-methyl-4-phenoxyaniline | 72920-03-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-methyl-4-phenoxyaniline
• 英文别名: 4-phenoxy-N-methylaniline
• CAS: 72920-03-7
• 化学式: C₁₃H₁₃NO
• mdl: MFCD09743427
• 分子量: 199.252
• InChiKey: QQSPSNFFTXUJOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-4-phenoxyaniline 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.17h， 生成 (R)-benzyl 4-(dimethylamino)-3-(3-methyl-3-(4-phenoxyphenyl)-ureido)butanoate
  参考文献：
  名称：

  WO2008/109991

  摘要：

  公开号：
• 作为产物：
  描述：

  N-(4-苯氧基-苯基)-乙酰胺 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 水 、 乙二醇 、 mineral oil 为溶剂， 反应 1.08h， 生成 N-methyl-4-phenoxyaniline
  参考文献：
  名称：

  Dual Protonophore–Chitinase Inhibitors Dramatically Affect O. volvulus Molting

  摘要：

  The L3-stage-specific chitinase OvCHT1 has been implicated in the development of Onchocerca volvulus, the causative agent of ondiocerciasis. Closantel, a known anthelmintic drug, was previously discovered as a potent and specific OvCHT1 inhibitor. As closantel is also a known protonophore, we performed a simple scaffold modulation to map out the structural features that are relevant for its individual or dual biochemical roles. Furthermore, we present that either OvCHT1 inhibition or protonophoric activity was capable of affecting O. volvulus L3 molting and that the presence of both activities in a single molecule yielded more potent inhibition of the nematode's developmental process.

  DOI：

  10.1021/jm5006435

文献信息

• Palladium‐Catalyzed Methylation of Nitroarenes with Methanol
  作者：Lin Wang、Helfried Neumann、Matthias Beller

  DOI：10.1002/anie.201814146

  日期：2019.4.8

  procedure for the synthesis of N‐methyl‐arylamines directly from nitroarenes using methanol as green methylating agent was developed. The key to success is the use of a specific catalyst system consisting of palladium acetate and the ligand 1‐[2,6‐bis(isopropyl)phenyl]‐2‐[tert‐butyl(2‐pyridinyl)phosphino]‐1H‐Imidazole (L1). The generality of this protocol is demonstrated in the synthesis of more than 20

  开发了使用甲醇作为绿色甲基化剂直接从硝基芳烃合成N-甲基-芳基胺的方法。成功的关键是使用由乙酸钯和配位体的1- [2,6-双（异丙基）苯基] -2- [叔-丁基（2-吡啶基）膦基] -1的特定催化剂体系的ħ -咪唑（L1）。在相对温和的条件下合成20多种N-甲基-芳基胺证明了该方案的普遍性。将这种新颖的方法与使用相同催化剂的后续偶联工艺相结合，可以使芳香族硝基化合物有效地分散为包括药物分子在内的各种胺类。
• A Metal‐Free Direct Arene C−H Amination
  作者：Tao Wang、Marvin Hoffmann、Andreas Dreuw、Edina Hasagić、Chao Hu、Philipp M. Stein、Sina Witzel、Hongwei Shi、Yangyang Yang、Matthias Rudolph、Fabian Stuck、Frank Rominger、Marion Kerscher、Peter Comba、A. Stephen K. Hashmi

  DOI：10.1002/adsc.202100236

  日期：2021.6.8

  The synthesis of aryl amines via the formation of a C−N bond is an essential tool for the preparation of functional materials, active pharmaceutical ingredients and bioactive products. Usually, this chemical connection is only possible by transition metal-catalyzed reactions, photochemistry or electrochemistry. Here, we report a metal-free arene C−H amination using hydroxylamine derivatives under benign

  通过形成 CN 键合成芳胺是制备功能材料、活性药物成分和生物活性产品的重要工具。通常，这种化学连接只能通过过渡金属催化的反应、光化学或电化学来实现。在这里，我们报告了在良性条件下使用羟胺衍生物进行的无金属芳烃 C-H 胺化。即使在存在各种官能团的情况下，胺化试剂 TsONHR 和芳烃底物之间的电荷转移相互作用也能实现芳烃的化学选择性胺化。氧气对于有效转化至关重要，其对电子转移步骤的加速作用已通过实验证明。此外，
• BTK INHIBITOR
  申请人：Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

  公开号：US20170313683A1

  公开（公告）日：2017-11-02

  Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

  提供了一系列的BTK抑制剂，特别公开了一种由公式(I)、(II)、(III)或(IV)表示的化合物、药用可接受的盐、互变异构体或前药。
• [EN] NOVEL AMINOTETRALINE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS<br/>[FR] NOUVEAUX COMPOSES AMINOTETRALINE UTILES POUR SOIGNER LES TROUBLES ASSOCIES AU RECEPTEUR MCH
  申请人：7TM PHARMA AS

  公开号：WO2003087046A1

  公开（公告）日：2003-10-23

  Novel compounds of formula (I) which modulate MCH activity are disclosed in which A is a linker; Ar1 is an aryl or heteroaryl group; R1 and R2 are hydrogen, straight or branched alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, alkylheteroaryl groups and may be linked to each other; R3 is a hydrogen atom, Alk-, Alk-O-, hydroxy or keto group; R4 and R5 are hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, -CHO, nitrile, alkyl, alkenyl or alkynyl groups, -CF3, -OCF3, -SCF3; -SCH3, -SO2NH2, -SO2NHAlk, -SO2Nalk2, -SO2Alk; n is 1 or 2; R8 is halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups with 3-7 carbons, alkylcycloalkyl groups, alkylaryl groups, alkylheterocyclyl groups, heteroaryloxyl groups, alkylheteroaryl groups, arylalkoxy groups, aryloxy groups, alkoxy groups, dialkylamino groups, -CONHAlk, -CONHAr, -CONAlk2, -NHCO-Alk, -NHCO-Ar, -CO-Alk, -CO-Ar, -SCH3, -CF3, -OCF3, -SCF3; or R8 is R6-Ar2-B-; in which B is a connecting moiety; Ar2 is an aryl or heteroaryl group; R6 is an R5 group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.

  化合物的新结构式（I），其调节MCH活性的方法已被披露，其中A是一个连接物；Ar1是芳基或杂环芳基；R1和R2是氢、直链或支链烷基、烯基或炔基、环烷基、烷基环烷基、烷基芳基、烷基杂环烷基、烷基杂芳基，它们之间可能相互连接；R3是氢原子、烷基、烷氧基、羟基或酮基；R4和R5是氢、卤素原子、烷氧基、羟基、烷基氨基、二烷基氨基、羟基烷基、羧酰胺基、酰胺基、酰基、-CHO、腈基、烷基、烯基或炔基、-CF3、-OCF3、-SCF3、-SCH3、-SO2NH2、-SO2NHAlk、-SO2Nalk2、-SO2Alk；n为1或2；R8是卤素原子、烷基、烯基或炔基、含有3-7个碳的环烷基、烷基环烷基、烷基芳基、烷基杂环烷基、杂芳氧基、烷基杂芳基、芳基烷氧基、芳氧基、烷氧基、二烷基氨基、-CONHAlk、-CONHAr、-CONAlk2、-NHCO-Alk、-NHCO-Ar、-CO-Alk、-CO-Ar、-SCH3、-CF3、-OCF3、-SCF3；或R8是R6-Ar2-B-；其中B是连接基；Ar2是芳基或杂环芳基；R6是一个R5基团；这些化合物在治疗或预防肥胖、抑郁症、糖尿病、暴食症等方面是有用的。
• Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory
  申请人：Abbott Laboratories

  公开号：US05514702A1

  公开（公告）日：1996-05-07

  The present invention provides certain (substituted carbocyclic aryl)amidoalkyl- and (substituted heterocyclic aryl)amidoalkyl-N-Hydroxy urea compounds which inhibit lipoxygenase enzyme activity and are thus useful in the treatment of allergic and inflammatory disease states.

  这项发明提供了一些抑制脂氧合酶酶活性的（取代的碳环芳基）氨基烷基-和（取代的杂环芳基）氨基烷基-N-羟基脲化合物，因此在治疗过敏和炎症性疾病状态中具有用处。